Invion Ltd

ASX:IVX ISIN:AU000000IVX4

Invion Limited ASX:IVXInvion Ltd (ASX:IVX) (OTCMKTS:IVIXF) (FRA:7C8) is a life-science company that is leading the global research and development of the Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Asia Pacific excluding China (other than Hong Kong, which is included in the Territory), Macau, Taiwan and Japan to the Photosoft technology for all cancer indications. It also holds the exclusive rights to the technology in Asia Pacific (excluding Greater China) for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States for infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited.

 
 

News

Invion Limited (ASX:IVX) Prostate Cancer Trial Results

🕔9/18/2024 4:14:59 PM 3458

Invion Limited (ASX:IVX) wishes to announce that RMW Cho Group Limited (RMWC), the licensor of the Photosoft(TM) technology, has successfully completed a Phase II prostate cancer trial (ACTRN12621000633886) using a sublingual (under the tongue) formulation of INV043.

Read Full Article
###

1,339 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 15) (Last 30 Days: 61) (Since Published: 1339) 

Company Data

    Headquarters
  • 100 Albert Road
    South Melbourne VIC 3205
    Australia
  • Telephone
  • +61 3 9692 7222 
  • Principal Sector
  • Health & Pharm General 
  • Principal Industry
  • Healthcare 
  • E:
  • investor@inviongroup.com

More News Results

  • 2025/09/24: Change of Director's Interest Notice - Thian Chew*
  • 2025/09/24: Notification of cessation of securities - IVX*
  • 2025/08/28: Response to ASX Aware Letter*
  • 2025/08/27: Appendix 4G and Corporate Governance Statement*
  • 2025/08/27: Appendix 4E and Annual Report*
  • 2025/08/20: Notification regarding unquoted securities - IVX*
  • 2025/08/20: Application for quotation of securities - IVX*
  • 2025/08/20: Orphan Drug Designation Granted by U.S. FDA For Anal Cancer*
  • 2025/08/20: Response to ASX Price Query*
  • 2025/08/19: Trading Halt*
*refer to company website